Dr. Schmoll Discusses CHARTA Results in CRC

Hans-Joachim Schmoll, MD
Published: Saturday, Jul 01, 2017



Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/ Oncology, University Hospital Halle, discusses the results of the CHARTA study in colorectal cancer.

The final results and multivariate prognostic factor analysis of the CHARTA study, which evaluated FOLFOX and bevacizumab (Avastin) with or without irinotecan, were presented at the 2017 World Congress on Gastrointestinal Cancer.

Results showed that FOLFOX and bevacizumab plus irinotecan was superior to FOLFIRI plus bevacizumab, which was reported on previously in the TRIBE study.
 


Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/ Oncology, University Hospital Halle, discusses the results of the CHARTA study in colorectal cancer.

The final results and multivariate prognostic factor analysis of the CHARTA study, which evaluated FOLFOX and bevacizumab (Avastin) with or without irinotecan, were presented at the 2017 World Congress on Gastrointestinal Cancer.

Results showed that FOLFOX and bevacizumab plus irinotecan was superior to FOLFIRI plus bevacizumab, which was reported on previously in the TRIBE study.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x